Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 3/20 | 0.51 |
| ▸ | PLG | P00747 | 2/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.51 |
| ▸ | F11 | P03951 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | DHFR | P00374 | 4/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.37 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | TARS1 | P26639 | 1/20 | 0.36 |
| ▸ | C1S | P09871 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | KLK1 | P06870 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24252941 | 0.83 | F12 (0.60) | F12PLGKLKB1F11PRSS1 | |
| SCHEMBL26775949 | 0.83 | DHFR (0.37) | F12PLGKLKB1F11PRSS1 | |
| SCHEMBL24252646 | 0.78 | DHFR (0.36) | PLGMAP4K4DHFRFYN | |
| SCHEMBL26771329 | 0.76 | DHFR (0.36) | F12PLGKLKB1F11PRSS1 | |
| SCHEMBL25840844 | 0.76 | KLKB1 (0.46) | F12PLGKLKB1F11PRSS1 | |
| SCHEMBL24252618 | 0.74 | PDE10A (0.45) | DHFR | |
| Formic Acid SCHEMBL30453086 | 0.73 | DHFR (0.33) | MAP4K4DHFRFYN | |
| Formic Acid SCHEMBL25259596 | 0.73 | DHFR (0.33) | MAP4K4DHFRFYN | |
| Formic Acid SCHEMBL25304045 | 0.73 | KLKB1 (0.42) | F12PLGKLKB1F11PRSS1 | |
| SCHEMBL26067409 | 0.73 | KLKB1 (0.42) | F12PLGKLKB1F11PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | F12 29/4885PLG 260/4885KLKB1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.